-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

322.O1.6 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Safety and Efficacy of Non-Factor Therapy in Hemophilia Clinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Clinical Trials, Bleeding and Clotting, Bleeding Disorders, Biological, Adults, Hemophilia, Bispecific Antibody Therapy, Non-Biological, Clinical Research, Health Outcomes Research, Genetic Disorders, Clinically Relevant, Coagulant Drugs, Diseases, Pediatric, Real World Evidence, Therapies, Registries, Adverse Events, Young Adults, Surgical, Study Population
Sunday, December 12, 2021: 9:30 AM-11:00 AM
C211-C213, Level 2, Building C (Georgia World Congress Center)
Moderator:
and Steven W. Pipe, MD, University of Michigan
Disclosures:
Pipe: Sangamo Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Scientific Advisory Board; ASC Therapeutics: Consultancy, Other: Scientific Advisory Board; Apcintex: Consultancy; Bayer: Consultancy; Biomarin: Consultancy; Catalyst Biosciences: Consultancy; CSL Behring: Consultancy; Freeline: Consultancy; Grifols: Consultancy; HEMA Biologics: Consultancy; Novo Nordisk: Consultancy; Octapharma: Consultancy; Pfizer: Consultancy; Roche/Genentech: Consultancy; Sanofi: Consultancy; Takeda: Consultancy; Spark Therapeutics: Consultancy; uniQure: Consultancy; GeneVentiv: Consultancy, Membership on an entity's Board of Directors or advisory committees; YewSavin: Research Funding; Siemens: Research Funding.
9:30 AM

Claude Négrier, MD1, Johnny Mahlangu, BSc, MB BCh, MMed, FCPath2, Michaela Lehle3*, Pratima Chowdary4*, Olivier Catalani3*, Víctor Jiménez-Yuste5*, Benjamin M. Beckermann3, Christophe Schmitt3*, Cedric Hermans6*, Giuliana Ventriglia3*, Jerzy Windyga7*, Anna Kiialainen3*, Roseline d'Oiron8*, Paul Moorehead9, Vanda Teodoro3*, Amy D. Shapiro10 and Johannes Oldenburg11*

1Louis Pradel Cardiology Hospital, Lyon 1 University, Lyon, France
2University of the Witwatersrand and NHLS, Johannesburg, Ga, South Africa
3F. Hoffmann-La Roche Ltd, Basel, Switzerland
4Royal Free London, London, United Kingdom
5Hospital Universitario La Paz, Autónoma University, Madrid, Spain
6Cliniques Universitaires Saint-Luc, Brussels, Belgium
7Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
8Bicêtre Hospital AP-HP, University Paris-Saclay and UMR_S1176 INSERM, Le Kremlin-Bicêtre, France
9Memorial University of Newfoundland, St. John's, NF, Canada
10Indiana Hemophilia and Thrombosis Center, Indianapolis, IN
11University of Bonn, Bonn, Germany

9:45 AM

Giancarlo Castaman1*, Jerzy Windyga2*, Hazza Alzahrani3*, Susan Robson4*, Fabian Sanabria4*, Monet Howard5* and Víctor Jiménez-Yuste6*

1Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy
2Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Blood Transfusion, Warsaw, Poland
3Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
4F. Hoffmann-La Roche Ltd, Basel, Switzerland
5F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada
6Hospital Universitario La Paz, Autónoma University, Madrid, Spain

10:00 AM

Allison P. Wheeler, MD1, Gary Benson2*, Hermann Eichler3*, Sidsel Marie Tønder, MSc4*, Katarina Cepo, MD5*, Victor Jimenez Yuste, MD, PhD6*, Kaan Kavakli, MD, PhD7*, Lily LL Wong, MD8* and Tadashi Matsushita9*

1Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN
2Northern Ireland Haemophilia Comprehensive Care Centre and Thrombosis Unit, Belfast, United Kingdom
3Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg/Saar, Germany
4Novo Nordisk A/S, Måløv, Denmark
5Biopharm Medical & Science, Novo Nordisk A/S, Søborg, Denmark
6Hospital Universitario La Paz, Madrid, Spain
7Department of Hematology, Ege University Faculty of Medicine, Children's Hospital, Izmir, Turkey
8Department of Hematology, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia
9Nagoya University Nagoya University Hospital Department of Blood Transfusion Service, Nagoya, Japan

10:15 AM

Heather Messenger1*, Chunla He2*, Michael Recht2 and Roshni Kulkarni1*

1Center for Bleeding and Clotting Disorders, Michigan State University, East Lansing, MI
2American Thrombosis and Hemostasis Network, Rochester, NY

10:30 AM

Man-Chiu Poon, MD1,2, Adrienne Lee, MD3, Federico Germini4*, Arun Keepanasseril4*, Quazi Ibrahim4*, Francis Nissen5*, Fabian Sanabria5*, Michelle Santos6*, Emma Iserman4*, Davide Matino4,7* and Alfonso Iorio4,7

1Department of Medicine, University of Calgary, Calgary, AB, Canada
2Department of Pediatrics and Oncology, University of Calgary, Calgary, AB, Canada
3Department of Medicine, Division of Hematology and Hematological Malignancies, University of Calgary, Calgary, AB, Canada
4Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
5F. Hoffmann-La Roche Ltd, Basel, Switzerland
6F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada
7Department of Medicine, McMaster University, Hamilton, ON, Canada

10:45 AM

Patrick Shane Ellsworth, MD1,2, Sheh-Li Chen, PharmD3, Christopher Wang4*, Nigel S Key2,5 and Alice Ma, MD6

1Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC
2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
3Eshelman School of Pharmacy, University of North Carolina, Durham, NC
4NC Eshelman School of Pharmacy, Chapel Hill
5Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC
6University of North Carolina At Chapel Hill, Chapel Hill, NC

*signifies non-member of ASH